RTP Mobile Logo
Select Publications

Adams R et al. Oral maintenance capecitabine versus active monitoring for patients with metastatic colorectal cancer (mCRC) who are stable or responding after 16 weeks of first-line treatment: Results from the randomized FOCUS4-N trial. ASCO 2021;Abstract 3504.

André T et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med 2020;383(23):2207-18. Abstract

Chau I et al. Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): First results of the CheckMate 648 study. ASCO 2021;Abstract LBA4001.

Cimino SK et al. Safety considerations with new treatment regimens for anal cancer. Expert Opin Drug Saf 2021;26:1-14. Abstract

Das S et al. All in the levels-programmed death-ligand 1 expression as a biomarker for immune checkpoint inhibitor response in patients with gastrointestinal cancer. Oncologist 2021;26(1):e186-8. Abstract

Finn RS et al. IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC). ASCO Gastrointestinal Cancers Symposium 2021;Abstract 267.

Jatoi A et al. Preemptive versus reactive topical clobetasol for regorafenib-induced hand-foot reactions: A preplanned analysis of the ReDOS trial. Oncologist 2021;[Online ahead of print]. Abstract

Kelly RJ et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021;384(13):1191-203. Abstract

Kelly RJ et al. Adjuvant nivolumab (NIVO) in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): Expanded efficacy and safety analyses from CheckMate 577. ASCO 2021;Abstract 4003.

Kuboki Y et al. The TRUSTY study: A randomized phase 2/3 study of trifluridine/tipiracil plus bevacizumab versus irinotecan and fluoropyrimidine plus bevacizumab as second-line treatment in patients with metastatic colorectal cancer. ASCO 2021;Abstract 3507.

Lee M et al. Phase II study of ipilimumab, nivolumab, and panitumumab in patients with KRAS/NRAS/BRAF wild-type (WT) microsatellite stable (MSS) metastatic colorectal cancer (mCRC). ASCO Gastrointestinal Cancers Symposium 2021;Abstract 7.

Moehler MH et al. First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) versus chemo in advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Expanded efficacy and safety data from CheckMate 649. ASCO 2021;Abstract 4002.

Roth MT et al. A randomized phase III study of immune checkpoint inhibition with chemotherapy in treatment-naive metastatic anal cancer patients: A trial of the ECOG-ACRIN cancer research group (EA2176). ASCO 2021;Abstract TPS3614.

Sahin IH et al. Mismatch repair (MMR) gene alteration and BRAF V600E mutation are potential predictive biomarkers of immune checkpoint inhibitors in MMR-deficient colorectal cancer. Oncologist 2021;[Online ahead of print]. Abstract

Sartore-Bianchi A et al. Phase II study of anti-EGFR rechallenge therapy with panitumumab driven by circulating tumor DNA molecular selection in metastatic colorectal cancer: The CHRONOS trial. ASCO 2021;Abstract 3506.

Shah MA et al. Multicenter, randomized phase II study of neoadjuvant pembrolizumab plus chemotherapy and chemoradiotherapy in esophageal adenocarcinoma (EAC). ASCO 2021;Abstract 4005.

Siena S et al. A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01. ASCO 2020;Abstract 4000.

Tabernero J et al. Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E-mutant metastatic colorectal cancer: Updated survival results and subgroup analyses from the BEACON study. J Clin Oncol 2021;39(4):273-84. Abstract

Tsuji A et al. The randomized phase II study of FOLFOXIRI plus cetuximab versus FOLFOXIRI plus bevacizumab as the first-line treatment in metastatic colorectal cancer with RAS wild-type tumors: The DEEPER trial (JACCRO CC-13). ASCO 2021;Abstract 3501.

Yoshino T et al. Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): Final results from a phase 2, multicenter, open-label study (DESTINY-CRC01). ASCO 2021;Abstract 3505.